Both SKOV3 and A2780 have hyperactive PI3K/AKT signaling due to mutations in PI3KCA and PTEN, respectively; however, their differential response to MEKi suggests that constitutively active AKT downstream is not prognostic of response to MEKi in ovarian cancer cells. This evidence concerns the gene AKT1 and ovarian cancer.